PMID- 20020139
OWN - NLM
STAT- MEDLINE
DCOM- 20120702
LR  - 20211020
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 1
DP  - 2012 Jan
TI  - A case of cellulitis causing tissue defect during etanercept therapy.
PG  - 241-4
LID - 10.1007/s00296-009-1281-0 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) antagonists are employed increasingly during 
      recent years in patients with active rheumatoid arthritis who do not respond to 
      disease-modifying anti-rheumatic drugs. Contraindications such as infections, 
      auto-antibody formation and hypersensitive reactions can be observed during the 
      treatment with TNF-alpha antagonist drugs. Our case was a 52-year-old woman, followed 
      by several centers for a period of 21 years with a seropositive, erosive and 
      nodular RA diagnosis. Anti TNF-alpha treatment was commenced due to the failure to 
      control the disease. During the treatment, a serious cellulite developed, which 
      required hospitalization and surgical debridement as well as intravenous 
      antibiotics treatment. Through the present case, we aimed to draw attention to 
      the skin infection during the use of etanercept in a patient with RA.
FAU - Deniz, Dulgeroglu
AU  - Deniz D
AD  - Department of Physical Therapy and Rehabilitation, Ankara Diskapi Yildirim 
      Beyazit Education and Research Hospital, Ministry of Health, Huzur mah 1157. sok 
      13-1/11 Dikmen Ankara Turkey, Ankara, Turkey. denizdulgeroglu@gmail.com
FAU - Ebru, Umay
AU  - Ebru U
FAU - Ajda, Bal
AU  - Ajda B
FAU - Gulsum, Tetik Menevse
AU  - Gulsum TM
FAU - Semih, Tatlican
AU  - Semih T
FAU - Aytul, Cakci
AU  - Aytul C
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20091218
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antirheumatic Agents/adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Cellulitis/*chemically induced/*diagnosis/therapy
MH  - Debridement
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2009/12/19 06:00
MHDA- 2012/07/03 06:00
CRDT- 2009/12/19 06:00
PHST- 2009/09/17 00:00 [received]
PHST- 2009/11/29 00:00 [accepted]
PHST- 2009/12/19 06:00 [entrez]
PHST- 2009/12/19 06:00 [pubmed]
PHST- 2012/07/03 06:00 [medline]
AID - 10.1007/s00296-009-1281-0 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Jan;32(1):241-4. doi: 10.1007/s00296-009-1281-0. Epub 2009 
      Dec 18.